Mesoblast (MESO) Change in Receivables (2016 - 2023)
Mesoblast (MESO) posted Change in Receivables of $9000.0 for Q1 2023, up 100.71% sequentially from -$1.3 million in Q4 2022, and down 97.81% YoY from $411000.0 in Q1 2022.
Mesoblast (MESO) Change in Receivables (2016 - 2023) Analysis & Trends
Mesoblast has reported Change in Receivables for 8 years, with the latest figure at $9000.0 in Q1 2023.
- Quarterly Change in Receivables fell 97.81% year-over-year to $9000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $499000.0 (up 132.79% YoY) and the FY2022 annual result came in at $140000.0, up 108.05% from the prior year.
- Change in Receivables rose to $9000.0 in Q1 2023 per MESO's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Change in Receivables peaked at $14.8 million in Q4 2019 and troughed at -$15.4 million in Q3 2019.
- A 5-year average of -$97294.1 and a median of $9000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2022: Change in Receivables jumped 551.56% in 2021, then slumped 197.64% in 2022.
- Over 5 years, Change in Receivables stood at $14.8 million in 2019, then plunged by 105.81% to -$858000.0 in 2020, then jumped by 50.58% to -$424000.0 in 2021, then plunged by 197.64% to -$1.3 million in 2022, then soared by 100.71% to $9000.0 in 2023.
- According to Business Quant data, Change in Receivables over the past three periods registered $9000.0, -$1.3 million, and $519000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | -1.26 Mn |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | 519,000.00 |
| Sep 30, 2022 | 519,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 411,000.00 |
| Mar 31, 2022 | 411,000.00 |
| Dec 31, 2021 | -424,000.00 |
| Dec 31, 2021 | -424,000.00 |
| Sep 30, 2021 | -1.08 Mn |
| Sep 30, 2021 | -1.08 Mn |
| Jun 30, 2021 | -429,000.00 |
| Jun 30, 2021 | -429,000.00 |
| Mar 31, 2021 | 417,000.00 |
| Mar 31, 2021 | 417,000.00 |
| Dec 31, 2020 | -858,000.00 |
| Dec 31, 2020 | -858,000.00 |